WO2009060473A2 - Injectable compositions, processes and uses thereof - Google Patents

Injectable compositions, processes and uses thereof Download PDF

Info

Publication number
WO2009060473A2
WO2009060473A2 PCT/IN2008/000757 IN2008000757W WO2009060473A2 WO 2009060473 A2 WO2009060473 A2 WO 2009060473A2 IN 2008000757 W IN2008000757 W IN 2008000757W WO 2009060473 A2 WO2009060473 A2 WO 2009060473A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
optionally
biocompatible
pharmaceutically acceptable
component
Prior art date
Application number
PCT/IN2008/000757
Other languages
French (fr)
Other versions
WO2009060473A3 (en
Inventor
Rajesh Jain
Sukhjeet Singh
Sampath Kumar Devarajan
Original Assignee
Panacea Biotec Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN2321/DEL/2007 priority Critical
Priority to IN2321DE2007 priority
Application filed by Panacea Biotec Limited filed Critical Panacea Biotec Limited
Publication of WO2009060473A2 publication Critical patent/WO2009060473A2/en
Publication of WO2009060473A3 publication Critical patent/WO2009060473A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Abstract

Injectable depot gel or implant compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocking agents, acetylcholinesterase inhibitors, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s) are provided. The present invention also describes process for preparation of such compositions and method of using such compositions.

Description

INJECTABLE COMPOSITIONS, PROCESSES AND USES THEREOF

FIELD OF THE INVENTION

The present invention describes single-component or a multi-component injectable compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha- 1 adrenergic blocking agents, acetylcholinesterase inhibitors or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and one or more pharmaceutically acceptable excipient(s), such that the said composition is in the form of ready-to-use liquid solution or dispersion, or a reconstitutable composition. The injectable compositions, of the present invention preferably form a depot upon administration in vivo and are in the form of an in situ gelling composition or an implant composition which provides a prolonged release of the active agent(s) for extended periods of time. Particularly the present invention relates to injectable depot compositions comprising as the active agent at least one antipsychotic preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin, or at least one acetylcholinesterase inhibitor preferably donepezil. The present invention also describes process for preparation of the compositions and method of using such compositions. The compositions of the present invention increase the efficacy of treatment associated with particularly chronic diseases, leading to greater patient compliance.

BACKGROUND OF THE INVENTION

It is often desirable to administer drugs using controlled or sustained release formulations that can maintain therapeutic blood levels of the active agent (drug) over extended periods of time. These controlled release formulations reduce the frequency of dosing for enhanced patient convenience and compliance, and also reduce the severity and frequency of associated side effects. By maintaining substantially constant blood levels and avoiding blood level fluctuations of the drug particularly associated with conventional immediate release formulations that are administered several times a day, controlled or sustained release formulations can provide a better therapeutic profile than is obtainable with conventional immediate release formulations. It is also often desirable to extend the release time of an injected drug to increase its duration of action, or to reduce its toxic effects. Formulations that are readily soluble in the body are usually absorbed rapidly and provide a sudden burst of available drug as opposed to a more desirable and gradual release of the pharmacologically active agent. This 'burst' release often results in a substantial portion of the beneficial agent, if not all, being released in a very short time, e.g., hours or 1-2 days. Several attempts have been made to provide controlled release injectable pharmaceutical compositions, but have not succeeded in overcoming certain problems associated with long acting parenteral dosage forms, such as achieving an extended release over desired period, stability in tissue fluids, reduced toxicity, reproducibility in preparations, and undesired physical, biochemical, or toxicological effects associated with dosage form compositions.

Where patient compliance is an issue, a probable approach is to design long acting dosage form compositions of the medication, that is, dosage forms where a single administration leads to a sustained release of the medication over an extended period of time. More recently formulations have been developed which are injected as a liquid, but undergo a change to a solid formulation in vivo, so-called 'in situ gelling systems'. These formulations can be injected intramuscularly or subcutaneously- through small bore needles and employ in particular biocompatible, solvents. Further, these 'in situ gelling systems' are patient compliant and they simplify the dosage regimen that a patient needs to adhere to, thus reducing the opportunity for non-compliance that occurs with a more rigorous schedule of frequent administration. Among such dosage forms is the depot formulation, which can be administered in various ways including intramuscularly or subcutaneously by injection. The depot injection is specifically formulated to provide a sustained release of the medication over an extended period of time like days, weeks, months or even up to years. Other method employed is the use of an implant which is a device which is either expelled from the animal once administration has completed or the implant breaks down in the animal and is expelled during normal bodily functions.

The use of injectable implants for the delivery of drugs is well known. Both biodegradeable and non-biodegradeable implant versions have been marketed since the 1980s. Examples of these are Zoladex®, a polylactide-co-glycolide formulation of goserelin for the treatment of breast cancer and Norplant®, a non-biodegradeable silicone device for contraception. Small, injectable microparticle based formulations are also well known, an example being Lupron Depot®, a formulation of leuprolide for the treatment of prostate cancer. A drawback of such preformed delivery systems is administration. Cylindrical rods such as Zoladex® require relatively large bore needles for implantation. However, injectable formulations comprising microparticles or nanoparticles allow smaller bore needles to be used for in vivo administration. The formulations are preferably in the form of microparticles which are difficult and highly cumbersome to formulate, and also require specialized manufacturing equipments and facilities. More recently formulations have been developed which are injected as a liquid, but undergo a change to a solid formulation in vivo, which are referred to as "in situ gelling systems".

Ziprasidone is a psychotropic agent which is indicated for treatment of schizophrenia. It is also known to possess moderate anti-depressant effects. Ziprasidone is available as GEODON® capsules containing monohydrochloride, monohydrate salt of ziprasidone in 20 mg, 40 mg, 60 mg and 80 mg strengths. Olanzapine is a psychotropic agent useful in the treatment of schizophrenia, acute manic episodes in bipolar disorder, acute agitation associated with both these disorders, maintenance treatment in bipolar disorder and for the treatment of depressive episodes associated with bipolar disorder. It is available as ZYPREXA® tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, or 20 ing strengths; ZYPREXA® ZYDIS® orally disintegrating tablets in 5 mg, 10 mg, 15 mg, or 20 mg strengths and ZYPREXA® IM injection wherein each vial provides 10 mg of olanzapine. Aripiprazole is an atypical antipsychotic approved for the treatment of schizophrenia. Aripiprazole is commercially available as ABILIFY® tablets in 2mg, 5mg, lOmg, 15mg, 20mg, and 30mg strengths.

Aromatase inhibitors are a class of compounds that act systematically to inhibit oestrogen synthesis in tissues. These compounds prevent oestrogen biosynthesis by inhibiting the enzyme aromatase, which catalyses the conversion of adrenal androgens (androstenedione and testosterone) to oestrogens (oestrogen and oestradiol). There has therefore been interest in developing these compounds as potential therapies for hormone responsive breast cancer in post-menopausal women. Anastrozole is a nonsteroidal aromatase inhibitor which is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Anastrozole is commercially available under the trade name ARIMIDEX® as 1 mg oral tablet. Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. Letrozole is commercially available under the trade name FEMARA® as 2.5 mg tablets for oral administration.

Tamsulosin is an alpha 1 -adrenoceptor blocking agent, which exhibits selectivity for alphal -receptors in the human prostate. Tamsulosin is used for the treatment of the symptoms associated with benign prostatic hyperplasia, such as bladder outlet obstruction, which is comprised of static and dynamic components. Tamsulosin hydrochloride is available under the trade name FLOMAX™ capsule containing 0.4 mg of tamsulosin hydrochloride. Donepezil is a known reversible inhibitor of acetylcholinesterase useful in the treatment of a variety of disorders, including dementia and attention deficit disorder. In particular, donepezil hydrochloride is employed as a pharmaceutically active agent for the symptomatic treatment of mild to moderate Alzheimer's dementia and is currently formulated as film-coated tablets of 5 mg and 10 mg doses for once a day oral administration available as ARICEPT®.

US Publication No. 20020034532 discloses injectable depot gel composition comprising a biocompatible polymer; a solvent that dissolves the biocompatible polymer and forms a viscous gel; a beneficial agent; and an emulsifying agent in the form of a dispersed droplet phase in the viscous gel. US patent No. 6287588 claims a dual phase polymeric agent delivery composition comprising a continuous biodegradable hydrogel phase, a discontinuous particulate phase comprising defined microparticles; and an agent to be delivered contained in at least said discontinuous particulate phase. The bioactive agent release is described to be modulated by microparticle phase alone or in both the microparticle and the gel matrix. The invention describes a reverse thermal gelation type of matrix. But the invention does not describe the experimental proof of polymeric hydrogel formation at the injection site by non solvent effect by a using an unhydrated cellulosic polymer in the reconstituted suspension composition having easy syringibility to be used as a depot injection. US publication no. 20060154918 discloses an injectable nanoparticulate olanzapine composition comprising olanzapine nanoparticles having an effective average particle size that results in a therapeutic efficacy of about one week or greater; at least one surface stabilizer; and a pharmaceutically acceptable carrier.

US publication no. 20050153841 discloses a formulation for parenteral administration to a subject, comprising at least one water miscible solvent; at least one gelling agent; and at least one active agent; characterized in that the gelling agent is in particulate form and suspended in the solvent. But the invention has not described the dual modulation of drug release patterns by means of simultaneously using gelling system dispersed with release controlling particulate form of drug in biodegradable microparticles. US publication no. 20040024069 describes an injectable depot composition comprising a bioerodible, biocompatible polymer; a solvent having a miscibility in water of less than or equal to 7% at 25°C, in an amount effective to plasticize the polymer and form a gel therewith, wherein said solvent is an aromatic alcohol; a thixotropic amount of a thixotropic agent mixed with the polymer solution effective to form a thixotropic composition, the thixotropic agent being selected from the group consisting essentially of lower alkanols and said amount being less than 15 weight percent of the combined weight of the solvent and the thixotropic agent; and a beneficial agent. US publication no. 20040138237 describes an injectable depot formulation that is viscous, or becomes viscous in situ, comprising a solubilised ziprasidone. The solubilised ziprasidone cyclodextrin lyophilized complex is suspended in non-aqueous viscosity agents like aluminum monostearate gelled sesame oil; and in situ gelling system such as e.g. stearic acid and N-methyl pyrrolidone.

PCT publication no. WO2007026145 describes a slow release anastrozole formulation, more particularly an in-situ gelling formulation comprising a polylactide polymer or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated. PCT publication no. WO2007026138 describes a slow release anastrozole formulation, more particularly to biodegradable polymers, typically a polylactide or poly(Iactide-co- glycolide) co-polymer, in which anastrozole is incorporated, including microparticle formulations and monolithic implant formulations. US patent no. 5,278,201 describes a biodegradable polymer for use in providing syringeable, in-situ forming, solid biodegradable implants for animals. Several attempts to provide dosage form compositions to sustain medication levels including the use of biodegradable materials for delivery of active agent for extended periods of time have been described previously. Many sustained release parenteral compositions can exhibit an increased release of biologically active agent over the first twenty-four hours after administration, commonly referred to as a burst. In some instances, this burst can result in an undesirable increase in the levels of biologically active agent leading to toxic effects and/or minimal release of agent thereafter providing sub-therapeutic concentration of the active agent. Therefore, a need still exists for methods of preparing sustained release parenteral depot composition where additional control over release kinetics by, for example, reducing the burst release of the active agent can be exerted and a continuous release of active agents for longer period of duration, for example, for a week or a month or for 3 months or more can be achieved, yet possessing good syringibility characteristics.

Further, the prolonged release compositions comprising biodegradable polymers needs to be delivered inside the body. In such cases, the drug is incorporated into the polymer and the mixture shaped into a certain form such a cylinder, disc, or fiber for implantation. With such solid implants, the composition has to be inserted into the body through an incision. These incisions are often larger than desired by the medical profession and lead to a reluctance of the patients to accept such an implant or drug delivery system. The only way to avoid the incision with these polymers is to inject them as small particles, microspheres, or microcapsules. Although these small particles can be injected into the body with a syringe, they do not always satisfy the demand for a uniform in-situ depot gel or a biodegradable implant. Because they are particles, they do not form a continuous film or solid implant with the structural integrity upon injection into the body. When these small particles, microspheres, or microcapsules come in contact with the bodily fluids, these are poorly retained because of their small size and discontinuous nature. In addition, microspheres or microcapsules prepared from these polymers and containing drugs for release into the body are sometimes difficult or are expensive to produce on a large scale, and their storage and injection characteristics present problems.

Also, there is an unmet need for depot injectable compositions particularly for long- term use that are clinically tolerable, effective and safe, have a low potential for causing morbidity, easy to manufacture, and are cost-effective. Such compositions would highly improve patient compliance since they would abolish the need for daily administration of the drug for substantially long duration of treatment. The present invention provides in situ gelling depot or implant compositions which alleviates the limitations of the prior art.

SUMMARY OF THE INVENTION

It is an objective of the present invention to provide injectable compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha- 1 adrenergic blocking agents, acetylcholinesterase inhibitors and pharmaceutically acceptable salts, derivatives, isomers, polymorphs,. solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvents), and optionally one or more pharmaceutically acceptable excipient(s), wherein said compositions provide a prolonged release of the active agent(s) for extended periods of time.

It is an objective of the present invention to provide injectable compositions comprising as the active agent at least one antipsychotic preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin, or at least one acetylcholinesterase inhibitor preferably donepezil, or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer (s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), which are in the form of an in situ gelling composition or an implant composition and which form a depot upon administration in vivo upon contact with body fluids thereby providing a prolonged release of the active agent for extended periods of time.

It is an objective of the present invention to provide a single-component or a multi- component injectable depot composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof from about 0.1% w/w to about 95% w/w; at least one biocompatible bioerodible polymer(s) in an amount of from about 0.1% w/w to about 95% w/w; at least one biocompatible non-toxic solvent(s) in an amount of from about 0.1% w/w to about 95% w/w and one or more pharmaceutically acceptable excipient(s) in an amount of from about 0% to about 99.8% w/w based upon the total weight of the composition, such that the said composition is in the form of ready-to-use liquid solution or dispersion, or a reconstitutable composition, and such that the said composition provides a prolonged release of the active agent(s) for extended periods of time.

It is an objective of the present invention to provide a single-component composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s), wherein the said composition is in the form of ready-to-use solution or dispersion.

It is an objective of the present invention to provide a multi-component composition comprising of at least two components component- 1 and component-2 such that the said composition is in the form of a reconstitutable composition, wherein component-1 comprises at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof, optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein component-2 for reconstitution of component-1 comprises at least one biocompatible non-toxic solvent(s), optionally at least one biocompatible bioerodible polymer(s) and optionally one or more excipient(s).

It is an objective of the present invention to provide injectable compositions comprising as the active agent at least one antipsychotic preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin, or at least one acetylcholinesterase inhibitor preferably donepezil, or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), and which is further diluted with an aqueous, hydro-alcoholic or oily liquid vehicle prior to parenteral administration.

It is an objective of the present invention to provide injectable compositions comprising at least one active agent selected from a group comprising ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil; at least oϊie biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the biocompatible bioerodible polymer(s) is a lactic or glycolic acid based polymer preferably polylactide polymer (PLA), or a polyglycolide polymer, or a poly(lactide-co- glycolide) co-polymer (PLGA); and wherein the said composition forms a gel or implant when placed in an aqueous physiological-type environment and releases the active agent for over a period of at least 3 days.

It is an objective of the present invention to provide a single-component or a multi- component injectable depot composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s), wherein the composition additionally comprises at least one gelling agent(s) preferably in an unhydrated form.

It is an objective of the present invention to provide a single-component or a multi- component injectable depot composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s), wherein the said biocompatible non-toxic solvent(s) is capable of dissolving or dispersing the active agent and the biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein upon administration in vivo the composition is capable of precipitating to form a substantially cohesive gel or implant almost instantaneously.

It is also an objective of the present invention to provide injectable depot compositions which provides a flowable composition for forming a solid or semi-solid biodegradable gel or implant in situ within a living body comprising ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil as active agent, at least one biocompatible bioerodible polymer(s) and at least one biocompatible nontoxic solvent(s), optionally at least one gelling agent(s) and optionally along with one or more pharmaceutically acceptable excipient(s), and wherein the composition upon in vivo administration exhibits minimal burst effect thus avoiding dose dumping and providing a sustained release of the active agent for a prolonged duration.

It is another objective of the present invention to provide a method of forming a depot gel or an implant in situ, in a living body, which comprises preparing an in situ gelling formulation according to the method described herein, placing the formulation within the body and allowing the liquid vehicle to disperse or dissipate to produce a solid or gel implant.

It is yet another objective of the present invention to provide a pharmaceutical kit suitable for in situ formation of a biodegradable depot gel or implant from the compositions as described herein, in the body of a subject in need thereof, which comprises a device containing ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil as active agent, optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutical acceptable excipient(s); and a device containing at least one biocompatible non-toxic solvent(s), optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); wherein the devices allow for expulsion of the contents of the two devices for enabling mixing together prior to administration of the contents into the body of the subject in need thereof.

It is another objective of the present invention to provide process for preparation of such injectable compositions which comprises mixing together the active agent(s), at least one biocompatible bioerodible polymer(s), at least one biocompatible non-toxic solvents), and optionally one or more pharmaceutically acceptable excipient(s) to form a single- component ready-to-use liquid solution or dispersion; or preparing a multi-component reconstitutable composition which comprises preparation of component- 1 using the active agent(s) alone or mixing the active agent(s) together with at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s), and preparation of component-2 using at least one biocompatible non-toxic solvent(s) alone or a dispersion or solution thereof comprising at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s) dispersed or dissolved in the biocompatible non-toxic solvent(s), and reconstituting the component- 1 using the component-2 prior to administration.

It is still another objective of the present invention to provide use of an in situ gelling formulation as described herein in the manufacture of a medicament for the treatment of a condition treatable by ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil in a mammal particularly a human being.

It is yet another objective of the present invention to provide a method of using the compositions of ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil according to the present invention which comprises administering to a subject/patient in need thereof an effective amount of the said composition.

Preferably the composition is administered to a subject particularly human or animal by injection, wherein the composition forms a drug depot that releases the pharmaceutically active agent(s) over a desired extended period of time, thereby increasing the efficacy of treatment associated with particularly chronic diseases, leading to greater patient compliance.

The compositions of the present invention preferably provide the active agent(s) to localize substantially in certain tissues, thereby increasing the efficacy of treatment, associated "with such tissues. The compositions of the present invention are useful for prophylaxis, amelioration and/or treatment of disease(s) or disorder(s) in a subject in need thereof.

DETAILED DESCRIPTION OF THE DRAWINGS

Figure 1: The said figure shows the in-vitro release profile of the composition as mentioned hereinafter in Example- 1.

Figure 2: The said figure shows the in-vitro release profile of the composition as mentioned hereinafter in Example-2. Figure 3: The said figure shows the in-vitro release profile of the composition as mentioned hereinafter in Example-3.

Figure 4: The said figure shows the plasma concentration vs. time of the composition

(Letrozole Depot Injection, SC) as mentioned hereinafter in Example-7.

Figure 5: The said figure shows the plasma concentration vs. time of the composition (Letrozole Depot Injection, IM) as mentioned hereinafter in Example-7.

Figure 6: The said figure shows the in-vitro release profile of the composition as mentioned hereinafter in Example- 8.

Figure 7: The said figure shows the in-vitro release profile of the composition as mentioned hereinafter in Example- 9. Figure 8: The said figure shows the plasma concentration vs. time of the composition

(Tamsulosin Depot Injection, IM) as mentioned hereinafter in Example-9.

Figure 9: The said figure shows the plasma concentration vs. time of the composition

(Tamsulosin SC) as mentioned hereinafter in Example-9.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides injectable compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha- 1 adrenergic blocking agents, acetylcholinesterase inhibitors and their pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s). The said compositions provide a prolonged release of the active agent(s) for extended periods of time.

The term "biocompatible" in the context of the present invention means not causing substantial tissue irritation or necrosis at the depot gel or implant site. The term "bioerodible" in the context of the present invention means that the implant erodes or degrades at its surfaces over time due, at least in part, to contact with substances found in the surrounding tissue fluids, or by cellular action. The term "non-toxic" implies that the agent does not cause any substantially potential toxicity upon in vivo use.

One of the biggest challenges in the development of solvent based depot injections in which the polymer is either dissolved or dispersed in a suitable solvent system is to overcome the development of high viscosity in the injectable' compositions. Such systems as a result of high viscosity are difficult to withdraw into the syringe as well as cause painful administration to the patient. Such compositions also cannot be filtered via simple technique such as membrane filtration. Thus the appropriate selection of a solvent system poses difficulties to the formulation scientist. It has now been surprisingly found by the inventors of the present invention that the solvents as disclosed in context of the present invention improve the syringibility by having a low viscosity. This decrease in viscosity leads to improved syringibility and requires only membrane filtration step for sterilization thereby preventing the need for costly sterilization techniques such as gamma-radiation. Thus, patient compliance is enhanced which is paramount owing to low viscosity of the in-situ gelling composition in the instant invention as pain at injection site is considerably reduced compared to a conventional high viscosity injectable composition.

In an embodiment, the present invention provides injectable compositions comprising as the active agent at least one antipsychotic preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin, or at least one acetylcholinesterase inhibitor preferably donepezil; or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), which are in the form of an in situ gelling composition or an implant composition and which form a depot upon administration in vivo upon contact with body fluids therefore providing a prolonged release of the active agent for extended periods of time. The active agent 'ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil' wherever disclosed in the entire description of the present invention also encompasses its pharmaceutically acceptable salts, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms, derivatives or mixtures thereof.

The injectable compositions of the present invention aid in patient compliance as the compositions of the present invention provide the desired therapeutic plasma concentrations for optimum therapeutic benefit by abolishing the need to administer a dosage composition daily, which the present invention provides in the form of injectable compositions. The injectable compositions of the present invention leads to less frequent dosing of drugs, and still provides an improved therapeutic effect with reduced side effects by effectively smoothening out the fluctuations in the plasma concentration-time profile. Most importantly, the prolonged release formulations of the present invention improves the "quality of life" of patients undertaking treatment with ziprasidone or olanzapine or aripiprazole for schizophrenia, anastrozole or letrozole for oncology indications, tamsulosin for Benign Prostatic Hyperplasia (BPH) particularly seen in older individuals, and donepezil for dementia associated with Alzheimer's disease and/or attention deficit disorder.

In an embodiment, the present invention provides injectable compositions comprising as the active agent at least one antipsychotic preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin, or at least one acetylcholinesterase inhibitor preferably donepezil, or , pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), which are in the form of an in situ gelling composition or an implant composition and which form a depot upon administration in vivo upon contact with body fluids thereby providing a prolonged release of the active agent for extended periods of time.

The amount of the active agent incorporated into the injectable, in-situ, solid forming implant depends upon the desired release profile, the concentration of drug required for a biological effect, and the length of time that the drug has to be released for treatment.

There is no critical upper limit on the amount of drug incorporated into the polymer solution except for that of an acceptable solution or dispersion viscosity for injection through a syringe needle. The lower limit of drug incorporated into the delivery system is dependent simply upon the activity of the drug and the length of time needed for treatment. For the purposes of this specification 'depot' is defined as a substance

(preferably containing an active agent) that is retained in close proximity to the site of injection so that release of the active agent occurs over a prolonged period of time. In an embodiment, the depot erodes/dissolves in the in vivo environment of a subject over time and in doing so releases the active agent into the subject.

In a preferred embodiment of the present invention is provided a single-component or a multi-component injectable depot composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof from about 0.1% w/w to about 95% w/w; at least one biocompatible bioerodible polymer(s) in an amount of from about 0.1% w/w to about 95% w/w; at least one biocompatible non-toxic solvent(s) in an amount of from about 0.1% w/w to about 95% w/w and one or more pharmaceutically acceptable excipient(s) in an amount of from about 0% to about 99.8% w/w based upon the total weight of the composition, such that the said composition is in the form of ready-to-use liquid solution or dispersion, or a reconstitutable composition, and such that the said composition provides a prolonged release of the active agent(s) for extended periods of time. The compositions are in the form of a clear solution or a homogeneous dispersion that are capable of forming a depot upon administration in vivo upon contact with body fluids therefore providing a prolonged release of the active agent for extended periods of time.

In an embodiment, the present invention provides a single-component composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more excipient(s), wherein the said composition is in the form of ready-to-use liquid solution or dispersion.

In another embodiment, the present invention provides a multi-component composition comprising of at least two components component- 1 and component-2 such that the said composition is in the form of a reconstitutable composition, wherein component-1 comprises at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof, optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein component-2 for reconstitution of component-1 comprises at least one biocompatible non-toxic solvent(s), optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s).

The compositions of the present invention are capable of producing a prolonged release of the active agents for at least 3 days preferably for a period of at least 7-15 days to 6 months or more. In another preferred embodiment, the biocompatible bioerodible polymer(s) is a lactic or glycolic acid based polymer preferably polylactide polymer (PLA), or a polyglycolide polymer, or a poly(lactide-co-glycolide) co-polymer (PLGA). The present invention provides injectable depot compositions comprising ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil as active agent which are flowable and which are capable of forming a solid or semi-solid biodegradable gel or implant in situ within a body. In another embodiment, the present invention provides an in situ gelling composition comprising the active agent and preferably a PLGA polymer, dissolved or dispersed or suspended in suitable solvent optionally further dissolved or dispersed or suspended in a liquid diluent such as an aqueous vehicle or an organic solvent or an oily vehicle. The compositions of the invention, upon contact with water or bodily fluids, result in the precipitation of both the polymer and the active agent and subsequent formation of a gel or an implant within which the active agent is incorporated. The active agent(s) subsequently diffuse from the gel or implant over an extended period of time to provide the desired pharmacological effect.

The term "flowable" in context of present invention means having a viscosity that will permit displacement of a material having this characteristic without application of pressure. A flowable composition is manipulatable, will pass through a small/moderate sized orifice without application of pressure and may be shaped/molded within tissue defect. Flowable compositions in this context include those having a consistency from that of an emulsion or suspension with a low viscosity or water-like consistency, to that of a high viscosity such as cold molasses.

In an embodiment, the single-component or a multi-component injectable depot composition of the present invention comprises at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s), wherein the said biocompatible non-toxic solvent(s) is capable of dissolving or dispersing the active agent and the biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein upon administration in vivo the composition is capable of precipitating to form a substantially cohesive gel or implant almost instantaneously. In another embodiment, the injectable depot compositions of the present invention provide a flowable composition for forming a solid or semi-solid biodegradable gel or implant in situ within a living body comprising ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil as active agent, at least one biocompatible bioerodible polymer(s) and at least one biocompatible nontoxic solvent(s), optionally at least one gelling agent(s) and optionally along with one or more pharmaceutically acceptable excipient(s), wherein the composition upon in vivo administration exhibits minimal burst effect thus avoiding dose dumping and providing a sustained release of the active agent for a prolonged duration.

In a further embodiment of the present invention is provided a single-component or a multi-component injectable depot composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s), wherein the composition additionally comprises at least one gelling agent(s) preferably in an unhydrated form.

In another embodiment, the present invention provides injectable compositions comprising at least one active agent selected from a group comprising ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable exciρient(s) in the form of a multi-component system preferably comprising at least two components.

In accordance with an aspect of the present invention is provided a two-component composition comprising of component- 1 and component-2 such that the said composition is in the form of a reconstitutable composition, wherein component-1 comprises at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof, optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein component-2 for reconstitution of component- 1 comprises at least one biocompatible non-toxic solvent(s), optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein the composition optionally comprise at least one gelling agent(s) either present in component- 1 or component-2 or both. The gelling agent(s) is present in an unhydrated form. In another embodiment, the gelling agent(s) is a biocompatible cellulosic polymer which acts as a stabilizer, active agent release modifier and/or a gel forming agent.

In an embodiment of the present invention, the gelling agent is selected from but not limited to group comprising cellulose derivatives, such as hydroxypropyl cellulose, hydroxy ethyl cellulose, hydroxypropyl methyl cellulose, methylcellulose, sodium carboxymethyl cellulose and its derivatives, vinyl polymers, polyoxyethylene- polyoxypropylene polymers or co-polymers (Pluronics®) such as PEO99-PPO67-PEO99 known as Pluronics F 127, polysaccharides such as glycosaminoglycans, agar, pectin, alginic acid, sodium alginate dextran, starch and chitosan, proteins, poly(ethyleneoxide), acrylamide polymers, polyhydroxy acids, polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols such as polyacrylic acid, polymethacrylic acid, polyvinyl pyrrolidone and polyvinyl alcohol, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polysiloxanes, polyvinyl acetates, polystyrene, polyurethanes, synthetic celluloses, polyacrylic acids, polybutyric acid, polyvaleric acid, poly(lactide-co-caprolactone), and copolymers, derivatives, and the like; or mixtures thereof. It is the applicant's understanding that the gelling agent forms a gel or semi-solid on dispersal of the solvent. For the purpose of this application, 'gel' is defined as a viscous or solid like material' formed by the aid of a suitable gelling agent. Such gels have a moderate to high viscosity that is they do not pour freely. These gelling agents are preferred due to their pharmaceutical and physiological acceptability and ability to form gels of desirable viscosity for use in such depot formation. Preferably the gelling agent(s) is a high viscosity grade of sodium carboxymethyl cellulose or methylcellulose. Preferably gelling agent is present in an amount between about 0.1 to about 50%, more preferably between about 0.5 to about 50% by weight of either component- 1 or component-2 or both.

In an embodiment, the present invention provides injectable compositions comprising at least one active agent selected from a group comprising ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the said biocompatible non-toxic solvent(s) is capable of dissolving or dispersing the active agent and/or the biocompatible bioerodible ρolymer(s); and wherein upon administration in vivo the composition is capable of precipitating to form a substantially cohesive gel or implant almost instantaneously.

In an embodiment of the present invention, the biocompatible bioerodible polymer is selected from but not limited to a group comprising lactic acid-based polymers such as polylactides e.g. poly (D,L-lactide) i.e. PLA; glycolic acid-based polymers such as polyglycolides (PGA) e.g. Lactel® from Durect; poly (D,L-lactide-co-glycolide) i.e. PLGA, (Resomer® RG-504, Resomer® RG-502, Resomer® RG-504H, Resomer® RG- 502H, Resomer® RG-504S, Resomer® RG-502S, from Boehringer, Lactel® from Durect); polycaprolactones such as Poly(e-caprolactone) i.e. PCL (Lactel® from Durect); polyanhydrides; poly(Sebacic acid) SA; poly(Ricenolic acid) RA; poly(Fumaric acid), FA; poly(Fatty acid dimmer), FAD; poly(terephthalic acid), TA; poly(isophthalic acid), IPA; poly(p-{carboxyphenoxy}methane), CPM; poly(p- {carboxyphenoxy} propane), CPP; poly(p-{carboxyphenoxy}hexane)s CPH; polyamines, polyurethanes, polyesteramides, polyorthoesters {CHDM: Cis/trans- cyclohexyl dimethanol, HD:l,6-hexanediol. DETOU: (3,9-diethylidene-2,4,8,10- tetraoxaspiro undecane)}; polydioxanones; polyhydroxybutyrates; polyalkyεne oxalates; polyamides; polyesteramides; polyurethanes; polyacetals; polyketals; polycarbonates; polyorthocarbonates; polysiloxanes; polyphosphazenes; succinates; hyaluronic acid; poly(malic acid); poly(amino acids); polyhydroxyvalerates; polyalkylene succinates; polyvinylpyrrolidone; polystyrene; synthetic celluloses; polyacrylic acids; polybutyric acid; triblock copolymers (PLGA-PEG-PLGA), triblock copolymers (PEG-PLGA-PEG), poly (N-isopropylacrylamide) (PNIPAAm), poly (ethylene oxide)- poly (propylene oxide)- poly (ethylene oxide) tri-block copolymers (PEO-PPO-PEO), poly valeric acid; polyethylene glycol; polyhydroxycellulose; chitin; chitosan; polyorthoesters and copolymers, terpolymers; lipids such as cholesterol, lecithin; poly(glutamic acid-co-ethyl glutamate) and the like, or mixtures thereof.

Preferably the biodegradable polymer is a lactic acid-based polymer, more preferably polylactide, or poly (D, L-lactide-co-glycolide) i.e. PLGA. Preferably the biodegradable polymer is present in an amount between about 10% to about 98% w/w of the component- 1. The lactic acid-based polymer has a monomer ratio of lactic acid to glycolic acid in the range of 100:0 to about 0:100 preferably 100:0 to about 10:90 and has an average molecular weight of from about 1,000 to 200,000 daltons. It might be emphasized that the choice and the quantity of biodegradable polymer is governed by the nature and quantity of active agent used, the desired particle size of the composition, the intended use, the duration of use, and the like. It might be emphasized that the choice and the quantity of biodegradable polymer is governed by the nature of active agent used, the intended use and the duration of use of the composition, and the like.

In an embodiment of the present invention, the biocompatible non-toxic solvent is selected from but not limited to a group comprising triacetin, ethanol, bezyl alcohol, 1-butanol, 2- butanol, chloroform, acetic acid, isopropyl alcohol, acetonitrile, N-methyl-2-pyrrolidone

(NMP), 2-pyrrolidone, miglyol, glycerol, methyl acetate, methyl isobutyl ketone, benzyl benzoate, propylene glycol, dimethyl isosorbide, propylene carbonate, ethyl acetate, ethyl lactate, dimethyl sulfone, N,N-diethyl-m-toluamide, methyl ethyl ketone, dimethylformamide, dichloromethane, benzonitrile, dimethyl isosorbide, dimethyl sulfoxide, dimethyl acetamide, tetrahydrofuran, caprolactam, decymethylsulfoxide, oleic acid, and l-dodecylazacyclo-heptan-2-one, and the like or mixtures thereof.

In an embodiment, the present invention provides injectable depot compositions comprising ziprasidone; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more excipient(s), wherein the solvent is selected from a group comprising N-methyl-2-pyrrolidone, dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), methyl isobutyl ketone, or mixtures thereof. In an embodiment, the present invention provides injectable depot compositions comprising olanzapine; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2-pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1-butanol, 2-butanol, or mixtures thereof.

In an embodiment, the present invention provides injectable depot compositions comprising aripiprazole; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2-pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1-butanol, 2-butanol, or mixtures thereof.

In an embodiment, the present invention provides injectable depot compositions comprising anastrozole; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2-pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1-butanol, 2-butanol, or mixtures thereof.

In an embodiment, the present invention provides injectable depot compositions comprising letrozole; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2-pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1-butanol, 2-butanol, or mixtures thereof.

In an embodiment, the present invention provides injectable ■ depot compositions comprising tamsulosin; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2-pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1-butanol, 2-butanol, or mixtures thereof.

In an embodiment, the present invention provides injectable depot compositions comprising donepezil; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2-pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1-butanol, 2-butanol, or mixtures thereof.

In another embodiment, the injectable compositions of the present invention comprising as the active agent at least one antipsychotic preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin, or at least one acetylcholinesterase inhibitor preferably donepezil, or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), is further diluted with an aqueous, hydro- alcoholic or oily liquid vehicle prior to parenteral administration.

In a further embodiment of the present invention, the liquid vehicle is in the form of an aqueous vehicle comprising water and optionally water miscible solvent selected from but not limited to group comprising preferably a water-miscible alcohol, for example, ethanol, n-propyl alcohol, isopropyl alcohol, tert-butyl alcohol, ethylene glycol or propylene glycol; dimethylsulfoxide; decylmethylsulfoxide; dimethylformamide; N- methyl-2-pyrrolidone; 2-pyrrolidone; acetone; methyl acetate; ethyl acetate; caprolactam; oleic acid, and l-dodecylazacycloheptan-2-one; a water-miscible ether, for example tetrahydrofuran; a water-miscible nitrile, for example acetonitrile; a water- miscible ketone, for example acetone or methyl ethyl ketone; an amide, for example dimethylacetamide; propylene glycol; glycerin, polyethylene glycol 400, glycofurol (tetraglycol), purified water and the like; or mixtures thereof. It is also preferred that the solvent for the biocompatible bioerodible polymer be non-toxic, water miscible, and otherwise biocompatible. Solvents that are toxic should not be used to inject any material into a living body. The solvents must also be biocompatible so that they do not cause severe tissue irritation or necrosis at the site of implantation. Furthermore, the solvent should be water miscible so that it will diffuse quickly into the body fluids and allow water to permeate into the polymer solution and cause it to solidify. Preferably the solvent is selected from a group comprising glycerin, ethanol, propylene glycol, polyethylene glycols, NMP, and purified water.

The solubility of the biodegradable polymers in the various solvents will differ depending upon their crystallinity, their hydrophilicity, hydrogen-bonding, and molecular weight. Thus, not all of the biodegradable polymers will be soluble in the same solvent, but each polymer or copolymer should have its optimum solvent. Lower molecular-weight polymers will normally dissolve more readily in the solvents than high-molecular-weight polymers. As a result, the concentration of a polymer dissolved in the various solvents will differ depending upon type of polymer and its molecular weight. Conversely, the higher molecular-weight polymers will normally tend to solidify faster than the very low-molecular-weight polymers. Moreover the higher molecular-weight polymers will tend to give higher solution viscosities than the low- molecular-weight materials. Thus for optimum injection efficiency, the molecular weight and the concentration of the polymer in the solvent have to be controlled. For example, low-molecular-weight polylactic acid formed by the condensation of lactic acid will dissolve in N-methyl-2-pyrrolidone (NMP) to give a 73% by weight solution which still flows easily through a 23-gauge syringe needle, whereas a higher molecular- weight poly (DL-lactide) (DL-PLA) formed by the additional polymerization of DL- lactide gives the same solution viscosity when dissolved in NMP at only 50% by weight. The higher molecular-weight polymer solution solidifies immediately when placed into water. The low-molecular-weight polymer solution, although more concentrated, tends to solidify very slowly when placed into water.

In another embodiment of the present invention, the liquid diluent is a lipophilic or oily vehicle comprising at least one oily component selected from but not limited to a group comprising vegetable oils such as corn oil, sesame oil, coconut oil, almond oil, sunflower oil, castor oil, etc. or a lipophilic compound such as dimethyl isosorbide, optionally with a surfactant selected from a group comprising anionic, cationic, non- ionic or zwitterionic surfactants and/or one or more other pharmaceutically acceptable excipient(s).

In another embodiment, the injectable depot compositions of the present invention comprise one or more pharmaceutically acceptable excipient(s) selected from but not limited to a group comprising one or more co-surfactants, solvents/co-solvents, water immiscible solvents, water, water miscible solvents, oily components, hydrophilic solvents, emulsifiers, preservatives, antioxidants, anti-foam ing agents, stabilizers, buffering agents, pH adjusting agents, osmotic agents, channel forming agents, isotonicity producing agents, or any other excipient known to the art that is soluble or miscible or dispersible in the biocompatible non-toxic solvent(s), or mixtures thereof.

In an embodiment of the present invention, the co-surfactant is selected from but not limited to a group comprising polyethylene glycols; polyoxyethylene- polyoxypropylene block copolymers known as "poloxamer"; polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate; sorbitan fatty acid ester such as sorbitan monostearate; polyoxyethylene sorbitan fatty acid ester such as polyoxyethylene sorbitan monooleate(TWEEN©); polyethylene glycol fatty acid ester such as polyoxyethylene monostearate; polyoxyethylene alkyl ether such as polyoxyethylene lauryl ether; polyoxyethylene castor oil and hardened castor oil, such as polyoxyethylene hardened castor oil; and the like or mixtures thereof. In an embodiment of the present invention, the solvent/cosolvent is selected from but not limited to a group comprising alcohols such as propylene glycol, polypropylene glycol, polyethylene glycol (such as PEG300, 400, 600, etc.), glycerol, ethanol, triacetin, dimethyl isosorbide, glycofurol, propylene carbonate, water, dimethyl acetamide, and the like or mixtures thereof. More preferably the solvent used is ethanol. The choice of solvent/cosolvent and its quantity primarily depends on solubility of active agent(s).

In an embodiment, the viscosity of the in-situ gelling composition is from about 1 cps to about 5000 cps. In another embodiment, the viscosity of the in-situ gelling composition is from about 1 cps to about 3000 cps. In yet another embodiment, the viscosity of the in-situ gelling composition is from about 1 cps to about 800 cps. Suitable anti-foaming agents include for example silicon emulsions or sorbitan sesquioleate. Suitable stabilizers to prevent or reduce the deterioration of the other components in compositions of the present invention include antioxidants such as glycine, alpha-tocopherol or ascorbate, BHA, BHT, and the like or mixtures thereof. Suitable tonicity modifier includes for example mannitol, sodium chloride, and glucose. Suitable buffering agent includes for example acetates, phosphates, and citrates with suitable cations. It might be however understood that certain excipient(s) used in the present composition can serve more than one purpose.

In an embodiment, the present invention provides a method of forming a depot gel or an implant in situ, in a living body, which comprises preparing an in situ gelling formulation according to the method described herein, placing the formulation within the body and allowing the liquid vehicle to disperse or dissipate to produce a solid or gel implant.

In another embodiment, the present invention provides a pharmaceutical kit suitable for in situ formation of a biodegradable depot gel or implant from the compositions as described herein, in the body of a subject in need thereof, which comprises a device containing ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil as active agent, optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutical acceptable excipient(s); and a device containing at least one biocompatible non-toxic solvent(s), optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); wherein the devices allow for expulsion of the contents of the two devices for enabling mixing together prior to administration of the contents into the body of the subject in need thereof.

In an embodiment, the present composition comprises additionally a thermogelling or hydrogelling polymer, or the biocompatible bioerodible polymer according to the present invention is a temperature sensitive biocompatible polymer, for example, a block copolymer having thermal gelation properties wherein the polymer is a gel at physiological temperatures (about 370C) and is a liquid above or below physiological temperatures would be functional. In the case of a gel having reverse thermal-gelation properties, the block copolymer would be a liquid at temperatures below the gelation temperature and would form a gel at above the gelation temperature. Conversely, a block copolymer having conventional thermal-gelation properties would be a liquid above the gelation temperature and a gel at or below the gelation temperature. When a biocompatible block copolymer having reverse thermal-gelation properties is employed, the active agent can be loaded in the block copolymer at below physiological temperatures such as room temperature. Because such block copolymers are soluble in water when cooled, the active agent may be easily loaded within the solution. Furthermore, when administered, the block copolymer solution, once in the gel state, is able to retain the active agent.

In yet another embodiment, the in-situ gel responds reversibly to a change in one or more in vivo conditions such as temperature, pH, solvent and ionic conditions. Particularly, the in situ gel is able to imbibe or solubilize a large amount of therapeutic agent and deliver a substantially linear and sustained release of therapeutic agent under physiological conditions.

In yet another embodiment of the present invention is provided a process for preparation of such injectable compositions which comprises mixing together the active agent(s), at least one biocompatible bioerodible polymer(s), at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s) to form a single-component ready-to-use liquid solution or dispersion; or preparing a multi-component reconstitutable composition which comprises preparation of component- 1 using the active agent(s) alone or mixing the active agent(s) together with at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s), and preparation of compbnent-2 using at least one biocompatible non-toxic solvent(s) alone or a dispersion thereof comprising at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s) dispersed in the biocompatible non-toxic solvent(s), and reconstituting the component-1 using the component-2 prior to administration.

In an embodiment is provided a process for the preparation of injectable composition according to the present invention, which comprises of the following steps: i) Dissolving or dispersing the active agent, biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s) in a biocompatible non-toxic solvent(s) and ii) Filling the material of step (i) into a syringe suitable for parenteral administration.

In an embodiment is provided a process for the preparation of injectable composition according to the present invention, which comprises of the following steps: i) Dissolving or dispersing the biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s) in a biocompatible non-toxic solvent(s), ii) Lyophilizing and filling the active agent(s) optionally mixed with one or more pharmaceutically acceptable excipient(s) in a vial, and iii) Reconstituting the material of step (ii) with the material of step (i) before administration.

In an embodiment is provided a process for the preparation of injectable composition according to the present invention, which comprises of the following steps: i) Mixing the sterile active agent(s), biocompatible bioerodible polymer(s) and optionally one or more excipient(s), ii) Filling the material of step (i) and the biocompatible non-toxic solvent(s) optionally comprising one or more pharmaceutically acceptable excipient(s) in separate chambers of pre-filled syringe, and iii) Mixing the materials of the pre-filled syringe before administration.

In an embodiment is provided a process for the preparation of injectable composition according to the present invention, which comprises of the following steps: i) Mixing the sterile active agent(s), biocompatible bioerodible polymer(s) and optionally one or more excipient(s), ii) Filling the material of step (i) in a syringe, iii) Filling the biocompatible non-toxic solvent(s) optionally comprising one or more pharmaceutically acceptable excipient(s) in a suitable container, and iv) Reconstituting the material of step (ii) using the material of step (iii) before administration. In another embodiment of the present invention is provided process for preparation of such composition which comprises of the following steps: i) Dissolving or dispersing the active agent(s), biocompatible bioerodible polymer(s) and optionally one or more excipient(s) in biocompatible non-toxic solvent(s), ii) Optionally making a liquid diluent composition (vehicle) comprising mixing a water miscible or immiscible solvent or an oily compound optionally with gelling agent(s) and/or other excipient(s), and iii) Optionally reconstituting the material of step (i) with the material of step (ii) before administration.

In an embodiment of the present invention is provided process for preparation of such composition which comprises of the following steps: i) Mixing the sterile active agent(s) with biocompatible bioerodible polymer(s), ii) Mixing the material of step (i) optionally with gelling agent and/or optionally with one or more excipient(s), iii) Dispersing material of step (ii) in a biocompatible non-toxic solvent(s) to form component- i, iv) Mixing the liquid diluent (vehicle) optionally with gelling agent(s) and/or other excipient(s) to form component- 2, and v) Mixing the component- 1 and component-2 to obtain the desired composition before administration.

In an embodiment, the composition of the present invention is preferably in the form of parenteral composition which can be administered to a subject, animals or humans, preferably via intramuscular, intradermal, cutaneous or subcutaneous routes. Specifically the parenteral composition according to the present invention can be administered by any of the following routes such as among others: intra-abdominal, intra-articular, intra-capsular, intra-cervical, intra-cranial, intra-ductal, intra-dural, intra- lesional, intra-ocular, intra-locular, intra-mural, intra-operative, intra-parietal, intraperitoneal, intra-plural, intra-pulmonary, intra-spinal, intra-thoracic, intra-tracheal, intra-tyrnpanic, intra-uterine or transdermal. In a preferred embodiment, the composition of the present invention is in the form of parenteral composition, which may be administered via intramuscular or subcutaneous route.

In an embodiment, the in-situ gelling composition according to the present invention can deliver the active agent directly to the target and provide short or long-term treatment by the sustained release of the active agent in the target area. The depot formed in vivo upon injection of the compositions according to the present invention is of a consistency selected from the group consisting of a viscous material, a gel or semisolid, and combinations thereof. The rate of release of the active agent from the depot might vary based on variation in one or more factors such as initial particle size, levels of gel in the formulation, the amount of active agent, levels of any additional materials in the formulation, the subject, subject metabolism, the administration site, and combinations thereof. A further advantage of the present invention is that leakage from the injection site is minimized or removed altogether. The biocompatible bioerodible polymer(s) that precipitates out upon contact with in vivo fluids instantaneously entraps substantially the active agent within close proximity of the injection site. This avoids back flow of formulation out through the injection point thus stopping unwanted waste of the agent and also gives a clean wound/administration area. In addition, the incorporation of a gelling agent into the composition of the present invention provides a better entrapment of the active agent and a lesser initial burst release of active agent after injection.

In yet another embodiment of the present invention is provided a method of forming a depot gel or an implant in situ, in a living body, which comprises preparing an in situ gelling formulation according to the method described herein, placing the formulation within the body and allowing the liquid vehicle to disperse or dissipate to produce a solid or gel implant.

In still another embodiment of the present invention is provided use of an in situ gelling formulation as described herein in the manufacture of a medicament for the treatment of a condition treatable by ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil in a mammal particularly a human being.

It is yet another objective of the present invention to provide a method of using the compositions of ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil according to the present invention which comprises administering to a subject/patient in need thereof an effective amount of the said composition. For example, the compositions of the present invention comprising ziprasidone are particularly useful for management such as prophylaxis, amelioration and/or treatment of subjects for the signs and symptoms of schizophrenia; compositions comprising olanzapine are particularly useful for management such as prophylaxis, amelioration and/or treatment of schizophrenia, acute manic episodes in bipolar disorder, acute agitation associated with both these disorders, maintenance treatment in bipolar disorder and depressive episodes associated with bipolar disorder; compositions comprising aripiprazole are particularly useful for management such as prophylaxis, amelioration and/or treatment of schizophrenia; compositions comprising anastrozole are particularly useful for management such as prophylaxis, amelioration and/or treatment of postmenopausal women with hormone receptor positive early breast cancer; compositions comprising letrozole are particularly useful for the management such as prophylaxis, amelioration and/or treatment of hormonally-responsive breast cancer; compositions comprising tamsulosin are particularly useful for management such as prophylaxis, amelioration and/or treatment of subjects for the signs and symptoms of benign prostatic hyperplasia; and compositions comprising donepezil are particularly useful for the management such as prophylaxis, amelioration and/or treatment of mild to moderate Alzheimer's dementia and attention deficit disorder. In still another embodiment is provided use of the composition according to the present invention comprising ziprasidone or olanzapine or aripiprazole as the active agent for the manufacture of a medicament for the prophylaxis, amelioration and/or treatment of signs and symptoms of schizophrenia. In another embodiment is provided the use of a composition according to the present invention comprising anastrozole or letrozole for the manufacture of a medicament for the prophylaxis, amelioration and/or treatment of subjects for oncology indications. In an embodiment is provided the use of a composition according to the present invention comprising tamsulosin for the manufacture of a medicament for the prophylaxis, amelioration' and/or treatment of subjects for Benign Prostatic Hyperplasia (BPH). In another embodiment is provided the use of a composition according to the present invention comprising donepezil for the manufacture of a medicament for the prophylaxis, amelioration and/or treatment of subjects for mild to moderate Alzheimer's dementia and attention deficit disorder.

Preferably the composition is administered to a subject particularly human or animal by injection, wherein the composition forms a drug depot that releases the pharmaceutically active agent(s) over a desired extended period of time, thereby increasing the efficacy of treatment associated with particularly chronic diseases, leading to greater patient compliance. The compositions of the present invention preferably provide the active agent(s) to localize in certain tissues, thereby increasing the efficacy of treatment, associated with such tissues. The compositions of the present invention are useful for prophylaxis, amelioration or treatment of disease(s) or disorder(s) in a subject in need thereof.

In an embodiment of the present invention, the compositions as mentioned hereinafter in Example-7 were subjected to bioavailability study conducted in healthy female rats. The protocol of the study is as follows:

Objective: The in-vivo pharmacokinetic profile of the above mentioned depot formulation in female rats via subcutaneous (SC) and intramuscular (IM) routes.

The selected rats of respective groups were administered depot formulation of letrozole subcutaneously and intramuscularly with 24/26 gauge needle and letrozole suspension per orally.

The in-vivo study for composition as mentioned hereinbefore was plotted as plasma concentration vs. time, the result of which is as follows:

Figure imgf000034_0001

Figure imgf000035_0001

Figure imgf000035_0002

In an another embodiment of the present invention, the compositions as mentioned hereinafter in Example 9 were subjected to bioavailability study conducted in New Zealand male rabbits (1.5-2.0 kg). The protocol of the study is as follows: Objective: The in-vivo pharmacokinetic profile of the above mentioned depot formulation in male rabbits.

The above mentioned formulation was injected to animal and plasma concentration of the drug was detected in the animals. The following table represents the plasma concentration of the drug in animals at various time intervals.

Figure imgf000036_0001

Figure imgf000037_0001

In yet another embodiment of the present invention, the compositions as mentioned hereinafter in Example-10 were subjected to bioavailability study conducted in male rats (250 g). The protocol of the study is as follows:

Objective: The in-vivo pharmacokinetic profile of the above mentioned depot formulation in male rat.

The above mentioned formulation was injected to animal and plasma concentration of the drug was detected in the animals. The following table represents the plasma concentration of the drug in animals at various time intervals.

Figure imgf000037_0002

Figure imgf000038_0001

The above-described exemplary embodiments are intended to be illustrative in all respects, rather than restrictive, of the present invention. Thus the present invention is capable of many variations in detailed implementation that can .be derived from the description contained herein by a person skilled in the art. All such variations and modifications are considered to be within the scope and spirit of the present invention.

The examples given below serve to illustrate embodiments of the present invention. However they do not intend to limit the scope of the present invention. Various experiments have been carried out on the present invention in order to ascertain the desirable viscosity of the injectable compositions which provide efficient syringibility of the injectables. This was done by selecting varied solvents selected from dimethylacetamide, dimethylisosorbide and N-methyl-2-pyrrolidone and different grades of polymers selected from PLGA 50/50 (low viscosity); PLGA 50/50 (high viscosity); PLGA 75/25 (low viscosity) and PLGA 75/25 (high viscosity) and their respective correlation amongst each other with respect to their impact on the final viscosity of the composition. It was concluded that the solvent dimethylacetamide along with polymer PLGA 50/50 (low viscosity) provided the most desirable viscosity, thus enhancing the syringibility of the injectable compositions.

A comparative data is represented as herein below which correlates the polymer with the solvent and thus substantiates the effective viscosity suitable for injectable compositions.

Figure imgf000039_0001

EXAMPLES

Example-1: Anastrozole depot injection S. No. Ingredient Quantity (g)/5 g

1. Anastrozole 0.3

2. Poly (DL-lactide-co-glycolide) 50/50 1.2

3. N, N Dimethyl Acetamide (DMA) 3.5 Procedure: i) Anastrazole was weighed and dissolved in the required amount of DMA. ii) Poly (DL-lactide-co-glycolide) (50/50) was added in the solution of step (i) after dissolving anastrazole in DMA. iii) The component of step (ii) was kept at 2-8°C for overnight. iv) The component of step (iii) was checked for any undissolved particles.

Example-2: Anastrozole depot injection

S. No. Ingredient Quantity (g)/4.5 g 1. Anastrozole 0.3

2. Poly(DL-lactide-co-glycolide) 50/50 1.2

3. N, N Dimethyl Acetamide (DMA) 3 Procedure: i) Anastrazole was weighed and dissolved in the required amount of DMA. ii) Poly (DL-lactide-co-glycolide) (50/50) was added in the solution of step (i) after dissolving anastrazole in DMA iii) The component of step (ii) was kept at 2-80C for overnight, iv) The component of step (iii) was checked for any undissolved particles.

Example-3: Anastrozole depot injection

S. No. Ingredient Quantity (g)/5.7 g

1. Anastrozole 0.3

2. Poly (DL-lactide-co-glycolide) 50/50 3

3. N, N Dimethyl Acetamide (DMA) 2.4 Procedure: i) Anastrazole was weighed and dissolved in the required amount of DMA. ii) Poly (DL-lactide-co-glycolide) (50/50) was added in the solution of step (i) after dissolving anastrazole in DMA iii) The component of step (ii) was kept at 2-80C for overnight iv) The component of step (iii) was checked for any undissolved particles.

Dissolution profile

Figure imgf000041_0001

Example 4: Letrozole depot injection

S. No. Ingredient Quantity (mg)/600 mg

1. Letrozole 75

2. Poly(DL-Iactide-co-glycolide) 75//25 (high viscosity) 150

3. N, N Dimethyl Acetaraide (DMA) 375 Procedure: i) Letrazole was weighed and dissolved in the DMA. ii) Poly (DL-lactide-co-glycolide) 75//25 (high viscosity) was added in the solution of step (i) after dissolving Letrazole in DMA. iii) The component of step (ii) was kept at 2-8°C for overnight, iv) The component of step (iii) was checked for any undissolved particles.

Example 5: Letrozole depot injection S. No. Ingredient Quantity(mg)/600 mg

1. Letrozole 75

2. Poly(DL-lactide-co-glycolide) 151125 (high viscosity) 125

3. N,N-Dimethyl Acetamide (DMA) 200

4. Dimethyl Isosorbide (DMI) 200 Procedure: » i) Letrazole was weighed and dissolved in the mixture of DMA and DMI. ii) Poly (DL-lactide-co-glycolide) 151125 (high viscosity) was added in the solution of step (i) after dissolving Letrazole in DMA and DMI. iii) The component of step (ii) was kept at 2-8°C for overnight, iv) The component of step (iii) was checked for any undissolved particles.

Example 6: Letrozole depot injection S. No. Ingredient Quantity(mg)/700 mg 1. Letrozole 75

2. Poly(DL-lactide-co-glycolide) 50/50 (low viscosity) 225

3. N, N-Dimethyl Acetamide (DMA) 400

Procedure: i) Letrazole was weighed and dissolved in the DMA. ii) Poly (DL-lactide-co-glycolide) 50/50 (low viscosity) was added in the solution of step (i) after dissolving Letrazole in DMA. iii) The component of step (ii) was kept at 2-80C for overnight. iv) The component of step (Hi) was checked for any undissolved particles.

Example 7: Letrozole depot injection

S. No. Ingredient Quantity(mg)/550 mg 1. Letrozole 75

2. Poly(DL-lactide-co-glycolide) 50/50 (low viscosity) 125

3. N, N-Dimethyl Acetamide (DMA) 350 Procedure: i) Letrazole was weighed and dissolved in the DMA. ii) Poly (DL-lactide-co-glycolide) 50/50 (low viscosity) was added in the solution of step (i) after dissolving Letrazole in DMA. iii) The component of step (ii) was kept at 2-80C for overnight, iv) The component of step (iii) was checked for any undissolved particles.

Example 8: Tamsulosin depot injection

S. No. Ingredient Quantity (g)/unit dose

1. Tamsulosin Hydrochloride 0.127

2. Poly(DL-lactide-co-glycolide) 50/50 0.874

3. N,N Dimethyl Acetamide (DMA) 6 Procedure: i) Tamsulosin was weighed and dissolved in the DMA. ii) Poly (DL-lactide-co-glycolide) 50/50 was added in the solution of step (i) after dissolving Tamsulosin in DMA. iii) The component of step (ii) was kept at 2-80C for overnight. iv) The component of step (iii) was checked for any undissolved particles. Dissolution profile

Figure imgf000044_0001

Example 9: Tamsulosin depot injection S. No. Ingredient Quantity (g)/unit dose

1. Tamsulosin base 0.096

2. Poly(DL-lactide-co-glycolide) 50/50 1.92

3. N,N-Dimethyl Acetamide (DMA) 1.46 Procedure: i) Tamsulosin was weighed and dissolved in the DMA. ii) Poly (DL-lactide-co-glycolide) 50/50 was added in the solution of step (i) after dissolving Tamsulosin in DMA. iii) The component of step (ii) was kept at 2-8°C for overnight, iv) The component of step (iii) was checked for any undissolved particles.

Dissolution profile

Figure imgf000044_0002
Figure imgf000045_0001

Example 10: Donepezil depot injection S. No. Ingredient Quantity(mg)/unit dose

1. Donepezil base 90

2. Poly (DL-lactide-co-glycolide) 75/25 360

3. N,N-Dimethyl Acetamide (DMA) 450 Procedure: i) Dozepezil was weighed and dissolved in the DMA. ii) Poly (DL-lactide-co-glycolide) 75/25 was added in the solution of step (i) after dissolving Dozepezil in DMA. iii) The component of step (ii) was kept at 2-80C for overnight, iv) The component of step (iii) was checked for any undissolved particles.

Dissolution profile

Figure imgf000045_0002
Example-11: Letrozole depot injection

S. No. Ingredient Quantity/unit dose (mg)

1. Letrozole 150

2. Poly(lactide-co-glycolide) co-polymer 400 3. N-methyl-2-pyrrolidone 2

Procedure: i) Poly(lactide-co-glycolide) co-polymer was dissolved in N-methyl-2-ρyrrolidone and suitably filled in an ampoule. ii) Letrozole was lyophilized and filled in a suitable vial. iii) Step (i) solution of Poly(lactide-co-glycolide) co-polymer is added to step (ii)

Letrozole powder and shaken well before administration.

Example-12: Tamsulosin depot injection

S. No. Ingredient Quantity/unit dose (mg) 1. Tamsulosin 12

2. Poly (lactide-co-glycolide) co-polymer 240

3. N-methyl-2-pyrrolidone 0.5 Procedure: i) Sterile Tamsulosin and Poly(lactide-co-glycolide) co-polymer were mixed together. ii) The material of step (i) and N-methyl-2-pyrrolidone were filled in separate chambers of pre-filled syringe, iii) The materials of the syringe are mixed together before administration.

Example-13: Ziprasidone depot injection

S. No. Ingredient Quantity/unit dose (mg)

1. Ziprasidone 150

2. Poly(lactide-co-glycolide) 240

3. N-methyl-2-pyrrolidone 2 Procedure: i) Poly(lactide-co-glycolide) is dissolved in N-methyl-2-pyrrolidone. ii) The solution is filtered through 0.2 micron and suitably filled in vial or ampoule. iii) Ziprasidone is filled in a suitable vial followed by sterilization of the same. iv) Step (ii) solution of Poly(lactide-co-glycolide) is added to step (iii) Ziprasidone powder and shaken well to obtain a uniform dispersion suitable for parenteral administration.

Example-14: Olanzapine depot injection

S. No. Ingredient Quantity/unit dose (mg)

1. Olanzapine 80

2. Poly(lactic acid) 250

3. N-methyl-2-pyrrolidone 1 Procedure: i) Poly (lactic acid) is dissolved in N-methyl-2-pyrrolidone. ii) The solution is filtered through 0.2 micron and suitably filled in vial or ampoule, iii) Sterile Olanzapine is filled in a suitable vial. iv) Step (ii) solution of Poly (lactic acid) is added to step (iii) Olanzapine powder and shaken well to obtain a uniform dispersion suitable for parenteral administration.

Example-15: Aripiprazole depot injection

S. No. Ingredient Quantity/unit dose (mg)

1. Aripiprazole 100 2. Poly (lactic acid) 100

3. N-methyl-2-pyrrolidone 1

Procedure: i) Sterile Aripiprazole and Poly (lactic acid) are mixed together, ii) The material of step (i) and N-methyl-2-pyrrolidone are filled in separate chambers of pre-filled syringe. iii) The materials of the syringe are mixed together before administration.

ExampIe-16: Anastrazole depot injection

S. No. Ingredient Quantity/unit dose (mg) 1. Anastrozole 30

2. Poly(Sebacic acid: Ricinoleic acid) 240

3. N-methyl-2-pyrrolidone 0.3 Procedure: i) Poly(Sebacic acid: Ricinoleic acid) is dissolved in N-methyl-2-pyrrolidone and suitably filled in an ampoule, ii) Sterile Anastrozole is filled in a suitable vial. iii) Step (i) solution of Poly(Sebacic acid: Ricinoleic acid) is added to step (ii)

Anastrozole powder and shaken well to reconstitute before administration.

Example-17: Anastrazole depot injection

S. No. Ingredient Quantity/unit dose (mg) 1. Anastrozole • 20

2. Poly(Sebacic acid: Ricinoleic acid) 240

3. N-methyl-2-pyrrolidone 1

4. Dimethyl acetamide 0.2 Procedure: i) Anastrozole is filled in a vial to form component- 1. ii) Poly (Sebacic acid: Ricinoleic acid) is dissolved in a mixture of N-methyl-2- pyrrolidone and Dimethyl acetamide to form component-2. iii) The component- 1 of step (i) is mixed with component-2 of step (ii) to obtain the desired composition before administration.

Claims

We claim:
1. An injectable composition comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha- 1 adrenergic blocking agents, acetylcholinesterase inhibitors and their pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s) wherein the said compositions provide a prolonged release of the active agent(s) for extended periods of time.
2. A composition according to claim 1, wherein the composition comprises as the active agent at least one antipsychotic preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin, or at least one acetylcholinesterase inhibitor preferably donepezil; or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein these are in the form of an in situ gelling composition or an implant composition and which form a depot upon administration in vivo upon contact with body fluids therefore providing a prolonged release of the active agent for extended periods of time.
3. A composition according to claim 1 or 2, wherein the composition is a single- component or a multi-component injectable depot composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof from about 0.1% w/w to about 95% w/w; at least one biocompatible bioerodible polymer(s) in an amount of from about 0.1% w/w to about 95% w/w; at least one biocompatible non-toxic solvent(s) in an amount of from about 0.1% w/w to about 95% w/w and one or more pharmaceutically acceptable eχcipient(s) in an amount of from about 0% to about 99.8% w/w based upon the total weight of the composition, such that the said composition is in the form of ready-to-use liquid solution or dispersion, or a reconstitutable composition, and such that the said composition provides a prolonged release of the active agent(s) for extended periods of time.
4. A composition of according to claim 3, wherein the composition is single- component composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more excipient(s), wherein the said composition is in the form of ready-to-use liquid solution or dispersion.
5. A composition according to claim 3, wherein the composition is a multi- component composition comprising of at least two components component- 1 and component-2 such that the said composition is in the form of a reconstitutable composition, wherein component- 1 comprises at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof, optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein component-2 for reconstitutiόn of component-1 comprises at least one biocompatible non-toxic solvent(s), optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s).
6. The composition according to any of the preceding claims 1 to 5, wherein the biocompatible bioerodible polymer(s) is a lactic or glycolic acid based polymer.
7. A composition according to claim 6, wherein the lactic or glycolic acid based polymer is polylactide polymer (PLA), or a polyglycolide polymer, or a poly
(lactide-co-glycolide) co-polymer (PLGA).
8. The composition according to any one of the preceding claims 1 to 7, wherein the composition provides in situ gelling composition comprising the active agent and preferably a PLGA polymer, dissolved or dispersed or suspended in suitable solvent optionally further dissolved or dispersed or suspended in a liquid diluent such as an aqueous vehicle or an organic solvent or an oily vehicle.
9. A composition according to claim 3, wherein the composition is the single- component or a multi-component injectable depot composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s), wherein the said biocompatible non-toxic solvent(s) is capable of dissolving or dispersing the active agent and the biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein upon administration in vivo the composition is capable of precipitating to form a substantially cohesive gel or implant almost instantaneously.
10. The composition according to any one of the preceding claims 1 to 9, wherein the compositions provide a flowable composition for forming a solid or semi-solid biodegradable gel or implant in situ within a living body comprising ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil as active agent, at least one biocompatible bioerodible polymer(s) and at least one biocompatible non-toxic solvent(s), optionally at least one gelling agent(s) and optionally along with one or more pharmaceutically acceptable excipient(s), wherein the composition upon in vivo administration exhibits minimal burst effect thus avoiding dose dumping and providing a sustained release of the active agent for a prolonged duration.
11. A composition according to claim 3, wherein the composition is a single- component or a multi-component injectable depot composition comprising at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s), wherein the composition additionally comprises at least one gelling agent(s) preferably in an unhydrated form.
12. The composition according to any one of the claims 1 to 11, wherein the composition comprises at least one active agent selected from a group comprising ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s) in the form of a multi-component system preferably comprising at least two components.
13. A composition according to claim 12, wherein the composition is a two- component composition comprising of component- 1 and component-2 such that the said composition is in the form of a reconstitutable composition, wherein component- 1 comprises at least one active agent(s) selected from a group consisting of ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof, optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein component-2 for reconstitution of component- 1 comprises at least one biocompatible non-toxic solvent(s), optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); and wherein the composition optionally comprise at least one gelling agent(s) either present in component- 1 or component-2 or both.
14. The composition according to any one of the claims 1 to 13, wherein the gelling agent(s) is a biocompatible cellulosic polymer which acts as a stabilizer, active agent release modifier and/or a gel forming agent.
15. A composition according to claim 14, wherein the gelling ag"ent is selected from but not limited to group comprising cellulose derivatives, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methylcellulose, sodium carboxymethyl cellulose and its derivatives, vinyl polymers, polyoxyethylene-polyoxypropylene polymers or co-polymers
(Pluronics®), such as PEO99-PPO67-PEO99 known as Pluronics F 127, polysaccharides such as glycosaminoglycans, agar, pectin, alginic acid, sodium alginate, dextran, starch and chitosan, proteins, poly(ethyleneoxide), acrylamide polymers, polyhydroxy acids, polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols such as polyacrylic acid, polymethacrylic acid, polyvinyl pyrrolidone and polyvinyl alcohol, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polysiloxanes, polyvinyl acetates, polystyrene, polyurethanes, synthetic celluloses, polyacrylic acids, polybutyric acid, polyvaleric acid, poly(lactide-co-caprolactone), and copolymers, derivatives, and the like; or mixtures thereof.
16. A composition according to claim 15, wherein the gelling agent is present in an amount between about 0.1 to about 50%, more preferably between about 0.5 to about 50% by weight of either component- 1 or component-2 or both.
17. The composition according to any one of the claims 1 to 16, wherein the injectable compositions comprising at least one active agent selected from a group comprising ziprasidone, olanzapine, aripiprazole, anastrozole, letrozole, tamsulosin and donepezil; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the said biocompatible non- toxic solvent(s) is capable of dissolving or dispersing the active agent and/or the biocompatible bioerodible polymer(s); and wherein upon administration in vivo the composition is capable of precipitating to form a substantially cohesive gel or implant almost instantaneously.
18. The composition according to any one of the claims 1 to 17, wherein the biocompatible bioerodible polymer is selected from a group comprising lactic acid-based polymers such as polylactides e.g. poly (D,L-lactide) i.e. PLA; glycolic acid-based polymers such as polyglycolides (PGA) e.g. Lactel® from Durect; poly (D,L-lactide-co-glycolide) i.e. PLGA5 (Resomer® RG-504, Resomer® RG-502, Resomer® RG-504H, Resomer® RG-502H, Resomer® RG-
504S, Resomer® RG-502S, from Boehringer, Lactel® from Durect); polycaprolactones such as Poly(e-caprolactone) i.e. PCL (Lactel® from Durect); polyanhydrides; poly(Sebacic acid) SA; poly(Ricenolic acid) RA; ρoly(Fumaric acid), FA; poly(Fatty acid dimmer), FAD; poly(terephthalic acid), TA; poly(isophthalic acid), IPA; poly(p-{carboxyphenoxy}methane), CPM; poly(p-
{carboxyphenoxy}propane), CPP; poly(p-{carboxyphenoxy}hexane), CPH; polyamines, polyurethanes, polyesteramides, polyorthoesters {CHDM: Cis/trans- cyclohexyl dimethanol, HD:l,6-hexanediol. DETOU: (3,9-diethylidene-2,4,8,10- tetraoxaspiro undecane)}; polydioxanones; polyhydroxybutyrates; polyalkyene oxalates; polyamides; polyesteramides; polyurethanes; polyacetals; polyketals; polycarbonates; polyorthocarbonates; polysiloxanes; polyphosphazenes; succinates; hyaluronic acid; poly(malic acid); poly(amino acids); polyhydroxyvalerates; polyalkylene succinates; polyvinylpyrrolidone; polystyrene; synthetic celluloses; polyacrylic acids; polybutyric acid; triblock copolymers (PLGA-PEG-PLGA), triblock copolymers (PEG-PLGA-PEG), poly
(N-isopropylacrylamide) (PNIPAAm), poly (ethylene oxide)- poly (propylene oxide)- poly (ethylene oxide) tri-block copolymers (PEO-PPO-PEO), polyvaleric acid; polyethylene glycol; polyhydroxycellulose; chitin; chitosan; polyorthoesters and copolymers, terpolymers; lipids such as cholesterol, lecithin; poly (glutamic acid-co-ethyl glutamate) and the like, or mixtures thereof.
19. A composition according to claim 18, wherein the biodegradable polymer is a lactic acid-based polymer, more preferably polylactide, or poly (D, L-lactide-co- glycolide) i.e. PLGA.
20. A composition according to claim 19, wherein the biodegradable polymer is present in an amount between about 10% to about 98% w/w of the component- 1.
21. A composition according to claim 19, wherein the lactic acid-based polymer has a monomer ratio of lactic acid to glycolic acid in the range of 100:0 to about 0:100 preferably 100:0 to about 10:90.
22. The composition according to any one of the claims 1 to 21, wherein the biocompatible non-toxic solvent is selected from a group comprising triacetin, ethanol, bezyl alcohol, 1-butanol, 2-butanol, chloroform, acetic acid, isopropyl alcohol, acetonitrile, N-methyl-2-pyrrolidone (NMP), 2-pyrrolidone, miglyol, glycerol, methyl acetate, methyl isobutyl ketone, benzyl benzoate, propylene glycol, dimethyl isosorbide, propylene carbonate, ethyl acetate, ethyl lactate, dimethyl sulfone, N,N-diethyl-m-toluamide, methyl ethyl ketone, dimethylformamide, dichloromethane, benzonitrile, dimethyl isosorbide, dimethyl sulfoxide, dimethylacetamide, tetrahydrofuran, caprolactam, decymethylsulfoxide, oleic acid, and l-dodecylazacyclo-heptan^-one, and the like or mixtures thereof.
23. The composition according to claim 1, comprising ziprasidone; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more excipient(s), wherein the solvent is selected from a group comprising N-methyl-2-pyrrolidone, dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), methyl isobutyl ketone, or mixtures thereof.
24. The composition according to claim 1, comprising olanzapine; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2- pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1- butanol, 2-butanol, or mixtures thereof.
25. The composition according to claim 1, comprising aripiprazole; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2- pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1- butanol, 2-butanol, or mixtures thereof.
26. The composition according to claim 1, comprising anastrozole; at least one biocompatible bioerodible ρolymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2- pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1- butanol, 2-butanol, or mixtures thereof.
27. The composition according to claim 1, comprising letrozole; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2- pyrrolidone; dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1- butanol, 2-butanol, or mixtures thereof.
28. The composition according to claim 1, comprising tamsulosin; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2- pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1- butanol, 2-butanol, or mixtures thereof.
29. The composition according to claim 1, comprising donepezil; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), wherein the solvent is selected from a group comprising ethylacetate, N-methyl-2- pyrrolidone, dimethylformamide, dimethyl sulfoxide, dimethyl acetamide, 1- butanol, 2-butanol, or mixtures thereof.
30. The composition according to claims 1 to 29, wherein the, injectable compositions comprises as the active agent at least one antipsychotic preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin, or at least one acetylcholinesterase inhibitor preferably donepezil, or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s), is further diluted with an aqueous, hydro-alcoholic or oily liquid vehicle prior to parenteral administration.
31. A composition according to claim 30, wherein the liquid vehicle is in the form of an aqueous vehicle comprising water and optionally water miscible solvent selected from group comprising preferably a water-miscible alcohol, for example, ethanol, n-propyl alcohol, isopropyl alcohol, tert-butyl alcohol, ethylene glycol or propylene glycol; dimethylsulfoxide; decylmethylsulfoxide; dimethylformamide;
N-methyl-2-pyrrolidone; 2-pyrrolidone; acetone; methyl acetate; ethyl acetate; caprolactam; oleic acid, and l-dodecylazacycloheptan-2-one; a water-miscible ether, for example tetrahydrofuran; a water-miscible nitrile, for example acetonitrile; a water-miscible ketone, for example acetone or methyl ethyl ketone; an amide, for example dimethylacetamide; propylene glycol; glycerin, polyethylene glycol 400, glycofiirol (tetraglycol), purified water and the like; or mixtures thereof.
32. The composition according to any one of the preceding claims 1 to 31, wherein the solvent is selected from preferably a group comprising glycerin, ethanol, propylene glycol, polyethylene glycols, NMP, and purified water.
33. A composition according to claim 30, wherein the liquid diluent is a lipophilic or oily vehicle comprising at least one oily component selected from a group comprising vegetable oils such as corn oil, sesame oil, coconut oil, almond oil, sunflower oil, castor oil, etc. or a lipophilic compound such as dimethyl isosorbide, optionally with a surfactant selected from a group comprising anionic, cationic, non-ionic or zwitterionic surfactants and/or one or more other pharmaceutically acceptable excipient(s).
34. The composition according to any one of the preceding claims 1 to 33, wherein the injectable depot compositions of the present invention comprise one or more pharmaceutically acceptable excipient(s) selected from a group comprising one or more co-surfactants, solvents/co-solvents, water immiscible solvents, water, water miscible solvents, oily components, hydrophilic solvents, emulsifϊers, preservatives, antioxidants, anti-foaming agents, stabilizers, buffering agents, pH adjusting agents, osmotic agents, channel forming agents, isotonicity producing agents, or any other excipient known to the art that is soluble or miscible or dispersible in the biocompatible non-toxic solvent(s), or mixtures thereof.
35. A composition according to claim 34, wherein the co-surfactant is selected from a group comprising polyethylene glycols; polyoxyethylene-polyoxypropylene block copolymers known as "poloxamer"; polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate; sorbitan fatty acid ester such as sorbitan monostearate; po Iy oxy ethylene sorbitan fatty acid ester such as polyoxyethylene sorbitan monooleate(TWEEN®); polyethylene glycol fatty acid ester such as polyoxyethylene monostearate; polyoxyethylene alkyl ether such as polyoxyethylene lauryl ether; polyoxyethylene castor oil and hardened castor oil, such as polyoxyethylene hardened castor oil; and the like or mixtures thereof; the solvent/cosolvent is selected from but not limited to a group comprising alcohols such as propylene glycol, polypropylene glycol, polyethylene glycol (such as PEG300, 400, 600, etc.), glycerol, ethanol, triacetin, dimethyl isosorbide, glycofurol, propylene carbonate, water, dimethyl acetamide, and the like or mixtures thereof; anti-foaming agents include for example silicon emulsions or sorbitan sesquioleate; suitable stabilizers to prevent or reduce the deterioration of the other components in compositions of the present invention include antioxidants such as glycine, alpha-tocopherol or ascorbate, BHA, BHT, and the like or mixtures thereof; suitable tonicity modifier includes for example mannitol, sodium chloride, and glucose; suitable buffering agent includes for example acetates, phosphates, and citrates with suitable cations.
36. A pharmaceutical kit suitable for in situ formation of a biodegradable depot gel or implant from the compositions according to claim 1, in the body of a subject in need thereof, which comprises a device containing ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil as active agent, optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutical acceptable excipient(s); and a device containing at least one biocompatible non-toxic solvent(s), optionally at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s); wherein the devices allow for expulsion of the contents of the two devices for enabling mixing together prior to administration of the contents into the body of the subject in need thereof.
37. The composition according to any one of the preceding claims 1 to 36, wherein the composition comprises additionally a thermogelling or hydrogelling polymer, or the biocompatible bioerodible polymer is a temperature sensitive biocompatible polymer, for example, a block copolymer having thermal gelation properties wherein the polymer is a gel at physiological temperatures (about 37°C) and is a liquid above or below physiological temperatures would be functional.
38. A composition according to any one of the preceding claims 1 to 37, wherein the viscosity of the injectable composition is from about 1 cps to about 5000 cps or from about 1 cps to about 3000 cps or from about 1 cps to about 800 cps.
39. A process for preparation of such injectable compositions according to any one of the preceding claims 1 to 36, which comprises mixing together the active agent(s), at least one biocompatible bioerodible polymer(s), at least one biocompatible non-toxic solvent(s), and optionally one or more pharmaceutically acceptable excipient(s) to form a single-component ready-to-use liquid solution or dispersion; or preparing a multi-component reconstitutable composition which comprises preparation of component- 1 using the active agent(s) alone or mixing the active agent(s) together with at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s), and preparation of component-2 using at least one biocompatible non-toxic solvent(s) alone or a dispersion thereof comprising at least one biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s) dispersed in the biocompatible non-toxic solvent(s), and reconstituting the component-1 using the component-2 prior to administration.
40. A process for the preparation of injectable composition according to any one of the preceding claims 1 to 36, which comprises of the following steps: i) Dissolving or dispersing the active agent, biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s) in a biocompatible non-toxic solvent(s) and ii) Filling the material of step (i) into a syringe suitable for parenteral administration.
41. A process for the preparation of injectable composition according to any one of the preceding claims 1 to 36, which comprises of the following steps: i) Dissolving or dispersing the biocompatible bioerodible polymer(s) and optionally one or more pharmaceutically acceptable excipient(s) in a biocompatible non-toxic solvent(s), ii) Lyophilizing and filling the active agent(s) optionally mixed with one or more pharmaceutically acceptable excipient(s) in a vial, and iii) Reconstituting the material of step (ii) with the material of step (i) before administration.
42. A process for the preparation of injectable composition according to any one of the preceding claims 1 to 36, which comprises of the following steps: i) Mixing the sterile active agent(s), biocompatible bioerodible polymer(s) and optionally one or more excipient(s), ii) Filling the material of step (i) and the biocompatible non-toxic solvent(s) optionally comprising one or more pharmaceutically acceptable excipient(s) in separate chambers of pre-filled syringe, and iii) Mixing the materials of the pre-filled syringe before administration.
43. A process for the preparation of injectable composition according to any one of the preceding claims 1 to 36, which comprises of the following steps: i) Mixing the sterile active agent(s), biocompatible bioerodible polymer(s) and optionally one or more excipient(s), ii) Filling the material of step (i) in a syringe, iii) Filling the biocompatible non-toxic solvent(s) optionally comprising one or more pharmaceutically acceptable excipient(s) in a suitable container, and iv) Reconstituting the material of step (ii) using the material of step (iii) before administration.
44. A process for preparation of such composition to any one of the preceding claims 1 to 36, which comprises of the following steps: i) Dissolving or dispersing the active agent(s), biocompatible bioerodible polymer(s) and optionally one or more excipient(s) in biocompatible nontoxic solvent(s), ii) Optionally making a liquid diluent composition (vehicle) comprising mixing a water miscible or immiscible solvent or an oily compound optionally with gelling agent(s) and/or other excipient(s), and iii) Optionally reconstituting the material of step (i) with the material of step (ii) before administration.
45. A process for preparation of such composition according to any one of the preceding claims 1 to 36, which comprises of the following steps: i) Mixing the sterile active agent(s) with biocompatible bioerodible polymer(s), ii) Mixing the material of step (i) optionally with gelling agent and/or optionally with one or more excipient(s), iii) Dispersing material of step (ii) in a biocompatible non-toxic solvent(s) to form component- 1, iv) Mixing the liquid diluent (vehicle) optionally with gelling agent(s) and/or other excipient(s) to form component- 2, and v) Mixing the component- 1 and component-2 to obtain the desired composition before administration.
46. The composition according to any one of the preceding claims 1 to 45, wherein the composition is preferably in the form of parenteral composition which can be administered to a subject, animals or humans, preferably via intramuscular, intradermal, cutaneous or subcutaneous routes.
47. A method of forming a depot gel or an implant in situ, in a living body according to claim 1, which comprises preparing an in situ gelling formulation according to the method described herein, placing the formulation within the body and allowing the liquid vehicle to disperse or dissipate to produce a solid or gel implant.
48. Use of an in situ gelling formulation according to claim 1 in the manufacture of a medicament for the treatment of a condition treatable by ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil in a mammal particularly a human being.
49. A method of using the compositions of ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil according to claim 1, which comprises administering to a subject/patient in need thereof an effective amount of the said composition.
50. A method according to claim 49, comprising ziprasidone particularly useful for management such as prophylaxis, amelioration and/or treatment of subjects for the signs and symptoms of schizophrenia; comprising olanzapine particularly useful for management such as prophylaxis, amelioration and/or treatment of schizophrenia, acute manic episodes in bipolar disorder, acute agitation associated with both these disorders, maintenance treatment in bipolar disorder and depressive episodes associated with bipolar disorder; comprising aripiprazole particularly useful for management such as prophylaxis, amelioration and/or treatment of schizophrenia; compositions comprising anastrozole are particularly useful for management such as prophylaxis, amelioration and/or treatment of postmenopausal women with hormone receptor positive early breast cancer; comprising letrozole particularly useful for the management such as prophylaxis, amelioration and/or treatment of hormonally-responsive breast cancer; compositions comprising tamsulosin are particularly useful for management such as prophylaxis, amelioration and/or treatment of subjects for the signs and symptoms of benign prostatic hyperplasia; and comprising donepezil particularly useful for the management such as prophylaxis, amelioration and/or treatment of mild to moderate Alzheimer's dementia and attention deficit disorder.
51. Use of the composition according to claim 1, comprising ziprasidone or olanzapine or aripiprazole as the active agent for the manufacture of. a medicament for the prophylaxis, amelioration and/or treatment of signs and symptoms of schizophrenia.
52. The injectable compositions and process for the preparation of injectable compositions substantially as herein described and illustrated by the examples.
PCT/IN2008/000757 2007-11-06 2008-11-06 Injectable compositions, processes and uses thereof WO2009060473A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN2321/DEL/2007 2007-11-06
IN2321DE2007 2007-11-06

Publications (2)

Publication Number Publication Date
WO2009060473A2 true WO2009060473A2 (en) 2009-05-14
WO2009060473A3 WO2009060473A3 (en) 2009-10-15

Family

ID=40626309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000757 WO2009060473A2 (en) 2007-11-06 2008-11-06 Injectable compositions, processes and uses thereof

Country Status (2)

Country Link
AR (1) AR070033A1 (en)
WO (1) WO2009060473A2 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394663A1 (en) * 2010-05-31 2011-12-14 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
WO2013063125A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
US20130171237A1 (en) * 2010-10-28 2013-07-04 Fotios M. Plakogiannis Aripiprazole compositions and methods for its transdermal delivery
JP2013528612A (en) * 2010-05-31 2013-07-11 ラボラトリオス ファルマセウティコス ロビ,ソシエダッド アノニマ Antipsychotics depot injectable compositions
WO2013142202A1 (en) * 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
WO2013142205A1 (en) * 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2014019972A1 (en) * 2012-08-03 2014-02-06 Laboratorios Farmacéuticos Rovi, S.A. Injectable compositions comprising letrozole or anastrozole
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2014160155A3 (en) * 2013-03-14 2014-11-13 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
CN104189954A (en) * 2014-09-19 2014-12-10 中国科学院长春应用化学研究所 In-situ tissue solidification engineering scaffold and preparation method thereof
US8980298B2 (en) 2011-10-24 2015-03-17 Braeburn Pharmaceuticals Bvba Sprl Implantable tizanidine compositions and methods of treatment thereof
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US9023897B2 (en) 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
US20150196485A1 (en) * 2010-05-31 2015-07-16 Laboratorios Farmacéuticos Rovi, S.A. Injectable Composition
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9138479B2 (en) 2011-10-31 2015-09-22 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
WO2017024027A1 (en) * 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US9687527B2 (en) 2010-07-19 2017-06-27 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US10226458B2 (en) 2011-03-18 2019-03-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0950403A2 (en) * 1998-04-14 1999-10-20 Atrix Laboratories, Inc. Emulsions for in-situ delivery systems
WO2000024374A1 (en) * 1998-10-28 2000-05-04 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2006053175A2 (en) * 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
WO2007026145A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Prolonged release formulations comprising anastrozole
WO2008041245A2 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
EP0950403A2 (en) * 1998-04-14 1999-10-20 Atrix Laboratories, Inc. Emulsions for in-situ delivery systems
WO2000024374A1 (en) * 1998-10-28 2000-05-04 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2006053175A2 (en) * 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
WO2007026145A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Prolonged release formulations comprising anastrozole
WO2008041245A2 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314424B2 (en) 2002-12-20 2016-04-19 Xeris Pharmaceuticals, Inc. Pastes for injection of a therapeutic agent
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
US8790679B2 (en) 2002-12-20 2014-07-29 Xeris Pharmaceuticals, Inc. Intracutaneous paste composition
US10058504B2 (en) 2010-05-31 2018-08-28 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
JP2013527213A (en) * 2010-05-31 2013-06-27 ラボラトリオス ファルマセウティコス ロビ,ソシエダッド アノニマ Depot compositions formulated method for injection
CN102933234A (en) * 2010-05-31 2013-02-13 罗维实验室制药股份公司 Methods for the preparation of injectable depot compositions
WO2011151356A3 (en) * 2010-05-31 2012-03-22 Laboratorios Farmacéuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
JP2013528612A (en) * 2010-05-31 2013-07-11 ラボラトリオス ファルマセウティコス ロビ,ソシエダッド アノニマ Antipsychotics depot injectable compositions
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10195138B2 (en) 2010-05-31 2019-02-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US20150196485A1 (en) * 2010-05-31 2015-07-16 Laboratorios Farmacéuticos Rovi, S.A. Injectable Composition
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
EA024211B1 (en) * 2010-05-31 2016-08-31 Лабораториос Фармасеутикос Рови, С.А. Methods for preparing injectable depot formulations
EP2394663A1 (en) * 2010-05-31 2011-12-14 Laboratorios Farmaceuticos Rovi, S.A. Compositions for injectable in-situ biodegradable implants
US9687527B2 (en) 2010-07-19 2017-06-27 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
CN103491961A (en) * 2010-10-28 2014-01-01 经皮给药药物研究实验室有限公司 Aripiprazole compositions and methods for its transdermal delivery
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
CN103491961B (en) * 2010-10-28 2018-01-02 艾库斯制药有限公司 Aripiprazole compositions and methods for percutaneous administration
US9138402B2 (en) * 2010-10-28 2015-09-22 Transdermal Research Pharm Laboratories, Llc Aripiprazole compositions and methods for its transdermal delivery
US20130209552A1 (en) * 2010-10-28 2013-08-15 Transdermal Research Pharm Laboratories, Llc Aripiprazole compositions and methods for its transdermal delivery
US20130171237A1 (en) * 2010-10-28 2013-07-04 Fotios M. Plakogiannis Aripiprazole compositions and methods for its transdermal delivery
US9023897B2 (en) 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US9339545B2 (en) 2011-03-10 2016-05-17 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US9295724B2 (en) 2011-03-10 2016-03-29 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US9302010B2 (en) 2011-03-10 2016-04-05 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US10226458B2 (en) 2011-03-18 2019-03-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
WO2013063125A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
AU2012328850B2 (en) * 2011-10-24 2017-02-02 Braeburn Pharmaceuticals, Inc. Implantable drug delivery compositions and methods of treatment thereof
US9011910B2 (en) 2011-10-24 2015-04-21 Braeburn Pharmaceuticals Bvba Sprl Implantable tizanidine compositions and methods of treatment thereof
US8980298B2 (en) 2011-10-24 2015-03-17 Braeburn Pharmaceuticals Bvba Sprl Implantable tizanidine compositions and methods of treatment thereof
CN103998026A (en) * 2011-10-24 2014-08-20 恩都医药解决方案公司 Implantable drug delivery compositions and methods of treatment thereof
US9138479B2 (en) 2011-10-31 2015-09-22 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
WO2013142205A1 (en) * 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142202A1 (en) * 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
WO2014019972A1 (en) * 2012-08-03 2014-02-06 Laboratorios Farmacéuticos Rovi, S.A. Injectable compositions comprising letrozole or anastrozole
KR101892109B1 (en) 2012-08-03 2018-09-28 라보라토리오스 파마슈티코스 로비, 에스.아. Injectable compositions comprising letrozole or anastrozole
AU2013298705B2 (en) * 2012-08-03 2018-03-08 Laboratorios Farmaceuticos Rovi, S.A. Injectable compositions comprising letrozole or anastrozole
CN104519870A (en) * 2012-08-03 2015-04-15 罗维实验室制药股份公司 Injectable compositions comprising letrozole or anastrozole
US10342877B2 (en) 2012-09-19 2019-07-09 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9861699B2 (en) 2012-09-19 2018-01-09 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US9642894B2 (en) 2013-02-06 2017-05-09 Xeris Pharmaceuticals, Inc. Compositions for rapidly treating severe hypoglycemia
WO2014160155A3 (en) * 2013-03-14 2014-11-13 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
US10238651B2 (en) 2014-03-20 2019-03-26 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US9526726B2 (en) 2014-03-20 2016-12-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10085980B2 (en) 2014-03-20 2018-10-02 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN104189954A (en) * 2014-09-19 2014-12-10 中国科学院长春应用化学研究所 In-situ tissue solidification engineering scaffold and preparation method thereof
WO2017024027A1 (en) * 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent

Also Published As

Publication number Publication date
WO2009060473A3 (en) 2009-10-15
AR070033A1 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
Packhaeuser et al. In situ forming parenteral drug delivery systems: an overview
KR100367144B1 (en) prolonged anesthesia in joints and body spaces
US6120789A (en) Non-polymeric sustained release delivery system
CN101669900B (en) Polymeric delivery formulations of leuprolide with improved efficacy
US8563027B2 (en) Drug delivery through hydrogel plugs
AU783538B2 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
KR100245395B1 (en) Formulations and methods for providing prolonged local anesthesia
US9265733B2 (en) Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
RU2532333C2 (en) Intraocular systems of sustained-release drug delivery and method of treating ophthalmic diseases
CA2691597C (en) Microspheres having core/shell structure
US6451335B1 (en) Formulations and methods for providing prolonged local anesthesia
JP5121790B2 (en) Biodegradable block copolymer compositions for drug delivery
AU2007223057B2 (en) Ocular therapy using sirtuin-activating agents
Choi et al. Controlled release of insulin from injectable biodegradable triblock copolymer depot in ZDF rats
Alexander et al. Poly (ethylene glycol)–poly (lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications
EP1581181B1 (en) Controlled release depot formulations
US9833548B2 (en) Methods and compositions for treating post-operative pain comprising clonidine
EP2361609B1 (en) Sustained release small molecule drug formulation
Parent et al. PLGA in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release
JP5795606B2 (en) Sustained release delivery formulation of risperidone compound
Heller et al. Poly (ortho esters)–their development and some recent applications
CN1538835A (en) Ophthalmic depot fomulations for periocular or conjunctival administration
KR20060109816A (en) Sustained release dosage forms of anesthetics for pain management
JP2009523771A (en) Individuals like taxanes lyophilized composition, method of producing the composition, a pharmaceutical preparation of the composition, preparation kit for the composition.
US20030049320A1 (en) Novel in-situ forming controlled release microcarrier delivery system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08846791

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08846791

Country of ref document: EP

Kind code of ref document: A2